Jasmiel Kit
Product Images NDC 50102-240

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Jasmiel (NDC 50102-240). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Afaxys Pharma, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Drospirenone Fig1)

A logarithmic scale chart showing the risk ratios of venous thromboembolism (VTE) with Yasmin relative to LNG-containing combined oral contraceptives (COCs). The chart includes hazard ratios, rate ratios, and odds ratios from various prospective and retrospective cohort studies, case-control studies, and non-fatal idiopathic cases only studies. Each study's risk ratio is plotted with confidence intervals, illustrating comparisons of VTE risk.*

FDA Label Image

Figure 2 (Drospirenone Fig2)

A horizontal bar chart titled 'Likelihood of Developing a VTE' comparing four groups: Non-Pregnant Non-COC users, COC users, Pregnancy, and Postpartum (12 weeks only). Each bar shows the range of number of women with a blood clot out of 10,000 women years, with Postpartum having the highest range (40 to 65) and Non-Pregnant Non-COC users the lowest (1 to 5). Pregnancy data is noted to be based on a nine-month duration assumption.*

FDA Label Image

Figure3 (Drospirenone Fig3)

A forest plot chart comparing effect estimates (odds ratios, relative risks, hazard ratios) with confidence intervals for studies on combined oral contraceptive (COC) use versus never-use and current COC use versus never-use. It includes study names, effect measures, and visual markers for each study's effect estimate along an effect scale from -1.50 to 2.00.*

FDA Label Image

Figure4 (Drospirenone Fig4)

A vertical chart illustrating birth control effectiveness related to pregnancy rates per 100 women per year. It lists methods from most to least effective, including implants, injections, intrauterine devices, sterilization, birth control pills, skin patch, vaginal ring, condoms, diaphragm, behavioral methods, spermicides, withdrawal, and no birth control.*

FDA Label Image

Figure5 (Drospirenone Fig5)

A weekly pill dosing chart for Jasmiel (Drospirenone and Ethinyl Estradiol Tablets) showing a 28-day layout with rows labeled Week 1 to Week 4 and columns for days of the week from Sunday to Saturday, marking the sequence for daily tablet intake in a kit.*

FDA Label Image

Figure6 (Drospirenone Fig6)

A horizontal bar chart illustrating the number of women with a blood clot per 10,000 women years (WY) for four groups: Non-Pregnant Non-COC users (1 to 5), COC users (3 to 9), Pregnant women (5 to 20), and Postpartum (12 weeks only) women, showing the highest range from 40 to 65. The chart includes a note about pregnancy duration assumptions affecting the data.*

FDA Label Image

Figure7 (Drospirenone Fig7)

Jasmiel Drospirenone and Ethinyl Estradiol Tablets USP, 3 mg / 0.02 mg kit label. The label indicates a single blister pack containing 28 tablets. The product is labeled by Afaxys Pharma, LLC, with NDC 50102-240-21. The label includes usage warnings and manufacturer information, noting the product is intended as an oral contraceptive and produced in the USA and India.*

FDA Label Image

Drospirenone Fig8

Packaging label for Jasmiel, a kit containing Drospirenone and Ethinyl Estradiol tablets USP, 3 mg/0.02 mg. The carton includes three individual pouches, each with one blister pack of 28 tablets. The label displays the NDC 50102-240-23 and identifies Afaxys Pharma, LLC as the labeler and Aurobindo Pharma Limited as the manufacturer. The design features a green and blue wave-like pattern on a white background.*

FDA Label Image

Chemical Str (Drospirenone Str)

Chemical structures of Drospirenone and Ethinyl Estradiol, the active ingredients in the Jasmiel oral contraceptive kit by Afaxys Pharma, LLC. The image shows the molecular diagrams for both hormone components.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.